Neo Ivy Capital Management Takes $1.20 Million Position in Agilent Technologies, Inc. $A

Key Points

• Neo Ivy Capital Management bought a new stake of 9,376 shares in Agilent Technologies during Q3, valued at about $1.20 million.
• Analysts hold a consensus rating of Moderate Buy with an average price target of $161.20; several firms raised targets or upgraded the stock and Goldman Sachs initiated coverage with a $170 buy rating.
• Agilent slightly missed the quarter (EPS $1.36 vs. $1.37 expected; revenue $1.80B, up 7% YoY), set FY2026 guidance of 5.900–6.040 EPS, and announced a $0.255 quarterly dividend (≈0.9% yield).

Neo Ivy Capital Management bought a new stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,376 shares of the medical research company's stock, valued at approximately $1,203,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Agilent Technologies by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company's stock valued at $4,012,086,000 after acquiring an additional 589,219 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Agilent Technologies by 10.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock worth $1,560,964,000 after acquiring an additional 1,273,994 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Agilent Technologies by 1.6% in the second quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company's stock valued at $860,137,000 after purchasing an additional 115,183 shares during the last quarter. Generation Investment Management LLP raised its holdings in shares of Agilent Technologies by 10.1% in the third quarter. Generation Investment Management LLP now owns 6,357,953 shares of the medical research company's stock valued at $816,043,000 after purchasing an additional 582,093 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Agilent Technologies during the second quarter valued at about $395,088,000.

Analyst Upgrades and Downgrades

A has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on shares of Agilent Technologies from $142.00 to $165.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 25th. The Goldman Sachs Group began coverage on shares of Agilent Technologies in a research report on Tuesday, December 9th. They set a "buy" rating and a $170.00 target price on the stock. Bank of America boosted their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 25th. TD Cowen reduced their target price on Agilent Technologies from $170.00 to $157.00 and set a "buy" rating for the company in a report on Thursday, February 26th. Finally, Evercore raised Agilent Technologies from an "in-line" rating to an "outperform" rating and increased their price target for the company from $155.00 to $160.00 in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $161.20.

Agilent Technologies Stock Performance

NYSE A opened at $115.11 on Friday. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $160.27. The company has a 50-day simple moving average of $132.65 and a 200 day simple moving average of $136.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.59 and a current ratio of 2.07. The company has a market capitalization of $32.53 billion, a PE ratio of 25.41, a price-to-earnings-growth ratio of 2.42 and a beta of 1.31.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The company had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. During the same period in the prior year, the firm posted $1.31 EPS. The business's revenue was up 7.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be paid a $0.255 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 annualized dividend and a yield of 0.9%. Agilent Technologies's dividend payout ratio is presently 22.52%.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.